Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 9/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241565 | 0.87 | PYCR1 (0.39) | CXCR3P2RX7PYCR1HDAC6HDAC3 | |
| SCHEMBL21241381 | 0.80 | P2RX7 (0.52) | CXCR3P2RX7PYCR1HDAC6HDAC3 | |
| SCHEMBL20683099 | 0.77 | P2RX7 (0.52) | CXCR3P2RX7PYCR1HDAC6HDAC3 | |
| SCHEMBL21241377 | 0.71 | HDAC6 (0.59) | HDAC6HDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL18088401 | 0.68 | P2RX7 (0.75) | CXCR3P2RX7PYCR1HDAC6HDAC3 | |
| SCHEMBL16327151 | 0.65 | PYCR1 (0.50) | CXCR3PYCR1CNR2NPSR1 | |
| SCHEMBL16312619 | 0.63 | PYCR1 (0.65) | PYCR1NPSR1 | |
| SCHEMBL21743358 | 0.63 | HDAC6 (0.70) | P2RX7HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL7297585 | 0.62 | PYCR1 (0.59) | PYCR1CNR2NPSR1 | |
| SCHEMBL12144256 | 0.58 | HRH3 (0.54) | PYCR1HDAC1CNR2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | CXCR3 3531/4885P2RX7 4700/4885PYCR1 2968/4885 |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | CXCR3 3531/4885P2RX7 4700/4885PYCR1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.